[{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s ML Bio Solutions Dosed First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Sachets","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Sachets","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I\/R9) Based on Glycosylated Alpha-dystroglycan (lgmd2i\/r9) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Surpasses Enrollment Target and Receives FDA Designation for BBP-418","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"BridgeBio Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ribitol

Ribitol
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Ribitol

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 2 USDMF, 2 JDMF, 1 NDC API, 1 Listed Suppliers

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 5 Listed Dossiers

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 5 SPI Pharma, 2 DKSH, 1 Jai Radhe Sales, 9 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 4 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 BASF, 1 Bioplus Life Sciences, 1 Clariant, 2 DFE Pharma, 4 Gangwal Chemicals, 2 Ingredion Pharma Solutions, 16 Kerry, 1 Kima Chemical, 5 Microlex e.U, 1 Nanjing Bold Chemical, 4 Pluviaendo, 17 Roquette, 7 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 4 Sigachi Industries, 1 The Dow Chemical Company, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

40 Fillers, Diluents & Binders, 20 Direct Compression, 14 Film Formers & Plasticizers, 13 Solubilizers, 12 Parenteral, 11 Thickeners and Stabilizers, 11 Co-Processed Excipients, 10 Coating Systems & Additives, 10 Taste Masking, 9 Granulation, 7 Topical, 5 Rheology Modifiers, 5 Emulsifying Agents, 5 Controlled & Modified Release, 5 Chewable & Orodispersible Aids, 5 Lubricants & Glidants, 5 Disintegrants & Superdisintegrants, 3 Surfactant & Foaming Agents, 2 API Stability Enhancers, 1 Soft Gelatin

DIGITAL CONTENT

2 NEWS #PharmaBuzz

2 NEWS #PharmaBuzz

MARKET PLACE

8 APIs, 1 EXCIPIENTS

REF. STANDARDS & IMPURITIES

1 USP, 1 Others

ANALYTICAL

1 Analytical Methods

1 Analytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

BridgeBio Pharma

U.S.A

Luxepack

Not Confirmed

02

BridgeBio Pharma

U.S.A

Luxepack

Not Confirmed

03

Bridge Biotherapeutics

South Korea

Luxepack

Not Confirmed

04

BridgeBio Pharma

U.S.A

Luxepack

Not Confirmed

05

BridgeBio Pharma

U.S.A

Discovery on Target

Not Confirmed